한글목차

전 세계 무표지 검출 시장은 2024년 6억 4,483만 달러에서 2033년에는 12억 5,149만 달러에 달할 것으로 예상되며, 예측 기간인 2025-2033년에는 7.5%의 CAGR로 성장할 것으로 예상됩니다.

무표지 검출은 형광 표지, 방사성 표지, 효소 표지 없이 분자의 물리적 특성 변화를 측정하는 첨단 분석 기술입니다. 결합 속도, 친화도, 농도에 대한 실시간 데이터를 제공하기 때문에 신약 개발, 리드 최적화, 바이오의약품 연구에 널리 활용되고 있습니다. 워크플로우를 간소화하고, 분석 개발 시간을 단축하며, 최소한의 샘플 조제로 복잡한 생물학적 시료를 분석할 수 있습니다.

시장 역학:

촉진요인과 억제요인

고도화된 신약 개발 프로세스에 대한 수요 증가

무표지 검출 시장은 첨단 신약 및 제품 개발 프로세스에 대한 수요 증가에 힘입어 성장하고 있습니다. 제약 및 생명공학 기업들은 생체분자 간 상호작용을 실시간으로 정확하게 측정하고, 데이터 품질을 향상시키며, 라벨 간섭을 줄이기 위해 이러한 기술을 선호하고 있습니다. 바이오의약품, 바이오시밀러, 맞춤의료에 대한 관심은 복잡한 생체분자 및 표적치료에 대한 상세한 분석을 가능하게 하는 이러한 기술의 채택을 가속화하고 있습니다.

또한, 무표지 검출 기술은 아티팩트를 줄인 생물학적으로 관련성이 높은 데이터를 제공함으로써 신약개발에 혁명을 일으키고 있습니다. 이러한 방법은 색소, 태그, 유전자 변형 세포를 필요로 하지 않기 때문에 네이티브 세포에서 생물학적 상호 작용을 보다 정확하게 표현할 수 있습니다. 또한, 민감도 향상, 실시간 동역학, 멀티 타겟 프로파일링도 가능합니다. 활용 분야에는 표현형 스크리닝, 표적 발굴 및 인증, 히트 투 리드 최적화, 독성 평가 등이 있습니다.

제한된 감도와 감지 범위

라벨이 없는 검출 기술은 감도와 검출 범위가 제한적이기 때문에 시장에서 어려움을 겪고 있습니다. 이러한 시스템은 실시간 분석을 제공하지만, 특히 복잡한 생물학적 시료에서 낮은 존재량의 생체분자나 약한 분자 간 상호작용을 감지할 때 타협할 수 있습니다. 이는 조기 바이오마커 탐색, 진단, 약물 스크리닝과 같은 중요한 응용 분야에서 정확성과 신뢰성에 영향을 미칩니다. 전통적인 표지 검출 방법이 여전히 선호되고 있으며, 이는 초민감성 검출 애플리케이션에서 무표지 기술의 채택을 제한할 수 있습니다.

목차

제1장 분석 방법과 분석 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 첨단 의약품 발견과 개발 프로세스에 대한 수요 증가
  • 성장 억제요인
    • 한정된 민감도와 검출 범위
  • 기회
  • 영향 분석

제5장 전략적 인사이트와 업계 전망

• 시장 리더와 선구자
  • 새로운 선구자와 주요 기업
  • 최대 매출을 자랑하는 브랜드를 확립한 리더
  • 확립된 제품을 보유한 시장 리더
• CXO의 견해
• 최신 개발과 혁신
• 사례 연구/진행중인 연구
• 규제와 상환 상황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• Porter's Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 수요와 격차
• 시장 진출 및 확장을 위한 추천 전략
• 시나리오 분석 : 베스트 케이스·기본 케이스·워스트 케이스 예측
• 가격 분석과 가격 시장 역학
• KOL(Key Opinion Leader)

제6장 제품 종류별

• 장비
• 소모품
• 소프트웨어·서비스

제7장 기술별

• 표면 플라즈몬 공명(SPR)
• 생체층 간섭측정법(BLI)
• 등온 적정 열량측정법(ITC)
• 시차 주사 열량측정법(DSC)
• 기타

제8장 용도별

• Drug Discovery & Development
• 동역학과 열역학 결합
• 히트 확인·리드 생성
• 내인성 수용체 검출
• 기타

제9장 최종사용자별

• 제약·바이오테크놀러지 기업
• 학술연구기관
• 의약품 임상시험수탁기관(CRO)
• 기타

제10장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제11장 경쟁 구도

• 경쟁 시나리오
• 시장 상황·점유율 분석
• M&A 분석

제12장 기업 개요

• Danaher Corporation
  • 기업 개요
  • 제품 포트폴리오
    • 제품 설명
    • 제품의 주요 실적평가 지표(KPI)
    • 제품 판매 실적과 예측
    • 제품 판매량
  • 재무 개요
    • 기업 매출
    • 매출 점유율 : 지역별
    • 매출 예측
  • 주요 동향
    • 기업 인수합병(M&A)
    • 주요 제품 개발 활동
    • 규제 당국 승인 등
  • SWOT 분석
• PerkinElmer, Inc
• Agilent Technologies, Inc
• Sartorius AG
• Thermo Fisher Scientific Inc
• Corning Incorporated
• Bruker Corporation
• HORIBA, Ltd.
• Reichert, Inc
• Malvern Panalytical Ltd
• Similar data will be provided for each market player.
• Attana AB
  • 파이프라인 제품 개요
  • 제품의 주요 실적평가 지표(KPI)
  • 주요 활동
  • 시장 진출 타임라인
  • 제품 보급률
  • 판매량 추정과 예측
• Nicoya
• Unchained Labs
• Nanotemper Technologies GmbH
• Creoptix AG
• 각 시장 진출 기업에 대해서도 같은 데이터가 제공됩니다.

제13장 부록

영문목차

The Global Label-Free detection market reached US$ 644.83 million in 2024 and is expected to reach US$ 1,251.49 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

Label-free detection is an advanced analytical technique that measures changes in the physical properties of molecules without the need for fluorescent, radioactive, or enzymatic labels. It provides real-time data on binding kinetics, affinity, and concentration, making it widely used in drug discovery, lead optimization, and biopharmaceutical research. It streamlines workflows, reduces assay development time, and allows for the analysis of complex biological samples with minimal sample preparation.

Market Dynamics: Drivers & Restraints

Growing Demand for Advanced Drug Discovery and Development Processes

The label-free detection market is driven by the increasing demand for advanced drug discovery and development processes. Pharmaceutical and biotechnology companies prefer these technologies for real-time, accurate measurement of biomolecular interactions, improving data quality and reducing label interference. The focus on biopharmaceuticals, biosimilars, and personalized medicine has accelerated the adoption of these technologies, enabling detailed analysis of complex biological molecules and targeted therapies.

Moreover, Label-free detection technologies are revolutionizing drug discovery by providing biologically relevant data with reduced artifacts. These methods eliminate the need for dyes, tags, or genetically modified cells, allowing for native cells and a more accurate representation of biological interactions. They also offer enhanced sensitivity, real-time kinetics, and multi-target profiling. Applications include phenotypic screening, target identification and validation, hit-to-lead optimization, and toxicity assessment.

Limited Sensitivity and Detection Range

Label-free detection technologies face challenges in the market due to their limited sensitivity and detection range. These systems offer real-time analysis but can be compromised when detecting low-abundance biomolecules or weak molecular interactions, especially in complex biological samples. This affects accuracy and reliability in critical applications like early-stage biomarker discovery, diagnostics, and drug screening. Traditional labeled detection methods may still be preferred, potentially limiting the adoption of label-free technologies in ultra-sensitive detection applications.

Segment Analysis

The global label-free detection market is segmented based on product type, technology, application, end user, and region.

The instruments in the product type segment are expected to dominate with the highest market share.

Instruments are crucial in the label-free detection, enabling the real-time study of biomolecular interactions. Advanced instruments like SPR analyzers, BLI systems, and ITC devices accurately measure binding kinetics, affinity, and thermodynamics without fluorescent or radioactive labels. Due to their rapid, reliable, and label-free results, these instruments are increasingly used in drug discovery, lead optimization, and biopharmaceutical development. Innovation in design, automation, and sensitivity enhancement is increasing demand across pharmaceutical, biotechnology, and research sectors.

For instance, in October 2024, Max Planck Institute researchers developed a method for precisely detecting small liquid quantities, down to micromolar levels, with exceptional sensitivity in the near-infrared spectrum. This breakthrough opens doors to advanced, label-free bio-imaging techniques for detecting target molecules in aqueous environments, pushing biomedical applications' boundaries.

Pharmaceutical and biotechnology companies in the end-user segment are the dominating with the highest market share.

The global label-free detection market is primarily driven by pharmaceutical and biotechnology companies, who rely on these technologies for drug discovery, biotherapeutics development, and biologics research. These companies use label-free systems for high-throughput screening, complex biological interactions analysis, and real-time data generation without labeling interferences. As the pharmaceutical industry shifts towards precision medicine, biologics, and small molecule therapeutics, demand for label-free detection technologies is expected to surge, solidifying their position as a primary growth driver.

Geographical Analysis

North America is expected to hold a significant position in the label-free detection market share

North America holds a substantial position in the label-free detection market due to the presence of a robust pharmaceutical and biotechnology sector, significant research investments, and prominent players like Danaher Corporation, Thermo Fisher Scientific, and Agilent Technologies. Also, the region's focus on drug discovery, early technology adoption, and government support for life sciences research fuel market growth. Market players' innovation in the region is a key driver for market growth in North America.

For instance, in February 2024, Agilent Technologies integrated the xCELLigence RTCA HT platform with the BioTek BioSpa 8 Automated Incubator, providing a non-invasive, label-free, kinetic readout of cell proliferation and cytotoxicity, thereby increasing throughput and decreasing sample sizes.

Competitive Landscape

The major global players in the label-free detection market include Danaher Corporation, PerkinElmer, Inc, Agilent Technologies, Inc, Sartorius AG, Thermo Fisher Scientific Inc, Corning Incorporated, Bruker Corporation, HORIBA, Ltd, Reichert, Inc, and Malvern Panalytical Ltd, among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Label-Free Detection market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Product Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Technology
• 3.3. Snippet by Application
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing Demand for Advanced Drug Discovery and Development Processes
  • 4.1.2. Restraints
    • 4.1.2.1. Limited Sensitivity and Detection Range
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Forces Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Instruments*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Consumables
• 6.4. Software and Services

7. By Technology

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 7.1.2. Market Attractiveness Index, By Technology
• 7.2. Surface Plasmon Resonance (SPR)*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Bio-layer interferometry (BLI)
• 7.4. Isothermal Titration Calorimetry (ITC)
• 7.5. Differential Scanning Calorimetry (DSC)
• 7.6. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Drug Discovery and Development*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Binding Kinetics and Thermodynamics
• 8.4. Hit Confirmation and Lead Generation
• 8.5. Endogenous Receptor Detection
• 8.6. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Pharmaceutical and Biotechnology Companies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Academic and Research Institutes
• 9.4. Contract Research Organizations (CROs)
• 9.5. Other

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

• 12.1. Danaher Corporation*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals, etc.
  • 12.1.5. SWOT Analysis
• 12.2. PerkinElmer, Inc
• 12.3. Agilent Technologies, Inc
• 12.4. Sartorius AG
• 12.5. Thermo Fisher Scientific Inc
• 12.6. Corning Incorporated
• 12.7. Bruker Corporation
• 12.8. HORIBA, Ltd.
• 12.9. Reichert, Inc
• 12.10. Malvern Panalytical Ltd
• Similar data will be provided for each market player.

Emerging Market Players

• 12.11. Attana AB*
  • 12.11.1. Pipeline Products Description
  • 12.11.2. Product Key Performance Indicators (KPIs)
  • 12.11.3. Key Activities
  • 12.11.4. Market Entry Timelines
  • 12.11.5. Product Penetration Rate
  • 12.11.6. Sales Estimation and Projections
• 12.12. Nicoya
• 12.13. Unchained Labs
• 12.14. Nanotemper Technologies GmbH
• 12.15. Creoptix AG
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us